The Exchange had sought clarification from Gallantt Ispat Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Financial results submitted is not as per format prescribed under Schedule III of the Companies Act, 2013 or as per Indian Accounting Standard The response of the Company is enclosed.
GALLANTT · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
NSE sought clarification from Gallantt Ispat regarding its Q4 and FY25 financial results, flagging that the submission did not match the format under Schedule III of the Companies Act or Indian Accounting Standards. The issue noted was that standalone and consolidated figures appeared identical. The company explained that Gallantt Medicity Developers Private Limited is an 'Associate' (not a subsidiary), has no revenue or profit, and therefore does not require line-by-line consolidation. The company confirmed full compliance with Schedule III and Ind AS requirements and asked the exchange to record the submission.
This is a routine procedural clarification with no financial or governance impact. Shareholders are not affected, and no penalty or action against the company has been indicated.